Why the study?
Does dabigatran prevent stroke and systemic embolization in patients with nonvalvular atrial fibrillation?
Does dabigatran prevent stroke and systemic embolization in patients with nonvalvular atrial fibrillation?
Dabigatran provides an effective and convenient alternative to warfarin for stroke prevention in nonvalvular atrial fibrillation, though its higher cost may limit widespread use.
Answers are grounded in this paper and cite their sources.
May offer a convenient alternative for stroke prevention in nonvalvular AF; leaves open cost-effectiveness questions in routine practice.
Dabigatran (Pradaxa) is a new oral anticoagulant approved in the United States for the primary prevention of stroke and systemic embolization in patients with nonvalvular atrial fibrillation. It offers clinicians an alternative to warfarin (Coumadin), and it has received considerable interest because of its convenience of use, clinical efficacy, and safety profile. However, it is more expensive, and this may limit its widespread use.
No takes yet. Share an insight, caveat, or question.
Wartak et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: